Australia's most trusted
source of pharma news
Wednesday, 15 January 2025
Posted 14 January 2025 AM
The TGA has dropped a 10-strong list of fast track approval pathways plus orphan drug designations handed out to companies late-2024, signalling a raft of new drugs set to be filed with the regulator in the coming months, if not sooner.
Among the list is AbbVie's antibody-drug conjugate (ADC) mirvetuximab soravtansine, which the company added to its pipeline in 2023 when it bought ImmunoGen for US$10.1 billion.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.